Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Atif J. Khan, Par S. Mehta, Thomas W. Zusag, Philip D. Bonomi, L. Penfield Faber, Susan Shott, Ross A. Abrams

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

Original languageEnglish (US)
Pages (from-to)163-167
Number of pages5
JournalRadiotherapy and Oncology
Volume81
Issue number2
DOIs
StatePublished - Nov 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Keywords

  • Lung cancer
  • NSCLC
  • Oligometastases
  • Oligometastasis

Fingerprint

Dive into the research topics of 'Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)'. Together they form a unique fingerprint.

Cite this